The content displayed in the BusinessYab Directory consists of information from third parties, among others from publicly accessible sources, or from customers, who have a presentation page in our directory. Further research generating real-world evidence on the role of DOACs to help inform the complex CAT clinical treatment decisions is warranted.Ĭancer Cancer associated thrombosis Direct oral anticoagulants Low molecular weight heparin Venous thromboembolism Warfarin.© 2023 All Rights reserved.Īt BusinessYab our purpose is to help people find great local businesses like dentists, hair stylists, restaurants, bars, hotels, local businesses. This study shows that DOACs are used as an inpatient/ED treatment option for CAT, and are associated with less post-discharge treatment switching and higher persistence and adherence. Outpatient treatment persistence and adherence appeared higher in patients using DOACs or warfarin versus LMWH or UFH. In addition, DOACs were the most common initial post-discharge outpatient therapy. Most DOAC patients remained on DOACs from inpatient/ED to outpatient settings (71.4%), while 24.1%, 43.5%, and 0.1% of patients treated with LMWH, warfarin, or UFH respectively, remained on the same therapy after discharge. Results showed that LMWH and unfractionated heparin (UFH) were the most common initial inpatient/ED CAT treatments (35.2% and 27.4%, respectively), followed by DOACs (9.6%) 20.8% of patients received no anticoagulants. This study assessed real-world treatment patterns of CAT in hospital/ED in adult cancer patients (≥ 18 years) diagnosed with CAT during a hospital visit in IQVIA's Hospital Charge Data Master database between Jand April 30, 2018, and followed their outpatient medical and pharmacy claims to evaluate the initial inpatient/ED and outpatient anticoagulants received within 3 months post-discharge. Little is known about the current utilization of DOACs in CAT patients, particularly on the inpatient to outpatient therapy transition. Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the recommended treatment options for cancer-associated thrombosis (CAT) in the 2019 National Comprehensive Care Network guidelines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |